Readoutin 14d
Janssen Research & Development, LLC — Cetrelimab
Phase 3 primary completion: TAR-200 in combination with Cetrelimab vs chemoradiotherapy in MIBC.
- Date
- Dec 2026
- Type
- Readout
- Ticker
- JNJ
- Indication
- Muscle-invasive bladder cancer (MIBC)
Readoutin 14d
Phase 3 primary completion: TAR-200 in combination with Cetrelimab vs chemoradiotherapy in MIBC.
The weekly brief is free. Pro adds reminders 7 days and 1 day before.